AUTHORS
Ariana Sabzevari, MS, Daniel Nguyen, BS2, Madison Turner, MS3, Luke Vass, MS4, Jayda Cavanaugh, BA5, Jeffrey W. Craig, MD, PhD6, Ipsita Pal, PhD7, Todd Fox, PhD8, Bishal Paudel, PhD9, Aakrosh Ratan, PhD10, David J Feith, PhD11, Thomas P Loughran, MD12
AFFILIATIONS
1 University of Virginia School of Medicine, Charlottesville, Virginia, United States
2 University of Virginia School of Medicine, Charlottesville, Virginia, United States
3 University of Virginia School of Medicine, Charlottesville, Virginia, United States
4 University of Virginia School of Medicine, Charlottesville, Virginia, United States
5 University of Virginia School of Medicine, Charlottesville, Virginia, United States
6 University of Virginia School of Medicine, Charlottesville, Virginia, United States
7 University of Virginia School of Medicine, Charlottesville, Virginia, United States
8 University of Virginia School of Medicine, Charlottesville, Virginia, United States
9 University of Virginia School of Medicine, Charlottesville, Virginia, United States
10 University of Virginia School of Medicine, Charlottesville, VA, United States
11 University of Virginia School of Medicine, Charlottesville, Virginia, United States, University of Virginia School of Medicine, Charlottesville, Virginia, United States
12 University of Virginia School of Medicine, Charlottesville, Virginia, United States, University of Virginia School of Medicine, Charlottesville, Virginia, United States
ABSTRACT
Introduction. Large granular lymphocyte leukemia (LGLL) is an incurable and understudied orphan disease with a standard of care that has minimally changed over the last four decades, highlighting a need to identify novel therapeutic strategies. While STAT3 activation is a hallmark of LGLL, direct STAT3 inhibition has failed to affect cell viability, suggesting alternative mechanisms sustain leukemic survival. While proinflammatory cytokines abundant in LGLL drive constitutive STAT3 activation, they also simultaneously initiate aberrant DNA methylation patterns. DNA hypermethylation has emerged as a unifying hallmark across T- and NK-LGLL subtypes, occurring independent of mutational status, but further amplified in STAT3-mutant patients. Mutations of epigenetic regulatory genes have been found to co-occur with STAT3 mutations in LGLL, positioning the epigenome as a target capable of engaging multiple oncogenic drivers simultaneously. We hypothesize that azacitidine (AZA), an FDA-approved hypomethylating agent (HMA), can be repurposed to reverse aberrant DNA methylation, restore silenced gene expression, and disrupt epigenomic programs sustaining LGLL.
Methods. Anti-leukemic efficacy of AZA was assessed by cell viability assays and flow cytometry analysis in T- and NK-LGLL cell lines and patient PBMCs stratified by STAT3 mutational status. Hypomethylating activity was evaluated by immunoblotting for DNMT1, DNMT3a, and DNMT3b and LCMS quantification of global 5-methylcytosine (5mC) levels. To characterize epigenomic and transcriptomic consequences of AZA, reduced representation bisulfite sequencing (RRBS), RNA sequencing, and assay for transposase-accessible chromatin (ATAC)-seq were utilized to simultaneously profile DNA methylation, gene expression, and chromatin accessibility in T- and NK-LGLL cell lines. Analyses employed both a candidate-based approach focused on known STAT3 negative regulators and an unbiased discovery approach to identify globally dysregulated genes and pathways. Readouts were designed to determine whether AZA-mediated hypomethylation can restore chromatin accessibility at silenced loci, reactivate tumor suppressor gene expression, and attenuate STAT3 signaling through promoter demethylation of its negative regulators. Phosphorylated STAT3 (pSTAT3) levels were assessed by immunoblotting and flow cytometry in cell lines and patient PBMCs, stratified by mutational status. Immunomodulatory effects were evaluated by multiplex cytokine profiling from supernatants of cells treated at non-cytotoxic doses. To address the limited availability of preclinical in vivo models in LGLL, a novel T-LGL leukemia mouse model was developed by engrafting NSG-huIL15 transgenic mice with luciferase-labeled human MOTN1 T-LGLL cells and utilized to evaluate AZA efficacy.
Results. AZA demonstrated significant dose- and time-dependent reductions in cell viability, DNMT protein levels, global 5mC levels, and increases in apoptotic markers such as cleaved caspase-3 and PARP in LGLL cell lines and primary patient samples. Multi-omic integration of RRBS, RNA-seq, and ATAC-seq confirmed genome-wide promoter demethylation with concordant chromatin opening and transcriptional reactivation of epigenetically silenced loci. Candidate-based analysis identified demethylation and reactivation of STAT3 negative regulators, while the unbiased discovery approach unveiled novel upregulated targets with therapeutic relevance, providing rationale for future combination strategies. AZA treatment significantly reduced pSTAT3 levels across cell lines and patient samples. Additionally, at non-cytotoxic doses, AZA reduced cytokines associated with T cell activation and JAK/STAT signaling while increasing anti-inflammatory mediators, outlining unique immunomodulatory capabilities. To increase translational relevance, in the NSG-IL15 T-LGLL in vivo mouse model, AZA induced a profound dose-dependent anti-leukemic effect evidenced by reductions in bioluminescence, splenomegaly, and hCD45 levels confirmed by flow cytometry and IHC/H&E analysis.
Conclusions. These findings demonstrate that targeting DNA hypermethylation with HMAs, such as AZA, is a clinically translatable strategy for LGLL validated across primary patient samples and a preclinical T LGLL mouse model. The integration of these datasets clarifies how epigenetic targeting in LGLL affects STAT3 activation and uncovers additional dysregulated pathways relevant to future combination strategies.
DISCLOSURES
Ariana Sabzevari, MS: No relevant conflicts of interest to declare.